Gunnar Nilsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10870803/publications.pdf Version: 2024-02-01



CHNNAD NUSSON

#	Article	IF	CITATIONS
1	The ingenious mast cell: Contemporary insights into mast cell behavior and function. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 83-99.	2.7	69
2	Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis. International Journal of Molecular Sciences, 2021, 22, 2964.	1.8	6
3	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere, 2021, 5, e646.	1.2	128
4	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics, 2020, 10, 10743-10768.	4.6	107
5	Divergent Effects of Acute and Prolonged Interleukin 33 Exposure on Mast Cell IgE-Mediated Functions. Frontiers in Immunology, 2019, 10, 1361.	2.2	31
6	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Research, 2017, 77, 1261-1270.	0.4	210
7	Curdlan induces selective mast cell degranulation without concomitant release of LTC4, IL-6 or CCL2. Immunobiology, 2017, 222, 647-650.	0.8	27
8	Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. Acta Dermato-Venereologica, 2016, 96, 602-612.	0.6	21
9	Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organization Journal, 2016, 9, 7.	1.6	124
10	IL-33 and Thymic Stromal Lymphopoietin in mast cell functions. European Journal of Pharmacology, 2016, 778, 68-76.	1.7	44
11	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. Journal of Allergy and Clinical Immunology, 2016, 137, 35-45.	1.5	289
12	Experimentallu Induced Psoriatic Lesions Associate with Rapid but Transient Decrease in Interleukin-33 Immunostaining in Epidermis. Acta Dermato-Venereologica, 2015, 95, 536-541.	0.6	16
13	Regulation of Mast Cell Survival and Apoptosis. Methods in Molecular Biology, 2015, 1220, 257-267.	0.4	5
14	Molecular targets on mast cells and basophils for novel therapies. Journal of Allergy and Clinical Immunology, 2014, 134, 530-544.	1.5	123
15	Developmental expression of IL-33 in the mouse brain. Neuroscience Letters, 2013, 555, 171-176.	1.0	28
16	Lipid mediator metabolic profiling demonstrates differences in eicosanoid patterns in two phenotypically distinct mast cell populations. Journal of Lipid Research, 2013, 54, 116-126.	2.0	36
17	Intraperitoneal influx of neutrophils in response to IL-33 is mast cell–dependent. Blood, 2013, 121, 530-536.	0.6	89
18	Mast Cells Respond to Cell Injury through the Recognition of IL-33. Frontiers in Immunology, 2012, 3, 82.	2.2	74

GUNNAR NILSSON

#	Article	IF	CITATIONS
19	Stress, the neuroendocrine system and mast cells: current understanding of their role in psoriasis. Expert Review of Clinical Immunology, 2012, 8, 235-241.	1.3	37
20	Anti-Apoptotic Bfl-1 Is the Major Effector in Activation-Induced Human Mast Cell Survival. PLoS ONE, 2012, 7, e39117.	1.1	13
21	Mast Cells Increase Vascular Permeability by Heparin-Initiated Bradykinin Formation InÂVivo. Immunity, 2011, 34, 258-268.	6.6	230
22	The Effect of Bacterial, Viral and Fungal Infection on Mast Cell Reactivity in the Allergic Setting. Journal of Innate Immunity, 2011, 3, 120-130.	1.8	16
23	Mast Cells as Sensors of Cell Injury through IL-33 Recognition. Journal of Immunology, 2011, 186, 2523-2528.	0.4	182
24	Mast Cell Apoptosis and Survival. Advances in Experimental Medicine and Biology, 2011, 716, 47-60.	0.8	31
25	Increased mast cell expression of PARâ€⊋ in skin inflammatory diseases and release of ILâ€8 upon PARâ€⊋ activation. Experimental Dermatology, 2010, 19, 117-122.	1.4	55
26	The BH3-Mimetic ABT-737 Induces Mast Cell Apoptosis In Vitro and In Vivo: Potential for Therapeutics. Journal of Immunology, 2010, 185, 2555-2562.	0.4	25
27	Mast Cell Survival and Mediator Secretion in Response to Hypoxia. PLoS ONE, 2010, 5, e12360.	1.1	46
28	Human Mast Cells Adhere to and Migrate on Epithelial and Vascular Basement Membrane Laminins LM-332 and LM-511 via α3β1 Integrin. Journal of Immunology, 2009, 183, 4657-4665.	0.4	11
29	TLR2/MyD88-Dependent and -Independent Activation of Mast Cell IgE Responses by the Skin Commensal Yeast <i>Malassezia sympodialis</i> . Journal of Immunology, 2009, 182, 4208-4216.	0.4	91
30	CD153 in Rheumatoid Arthritis: Detection of a Soluble Form in Serum and Synovial Fluid, and Expression by Mast Cells in the Rheumatic Synovium. Journal of Rheumatology, 2009, 36, 501-507.	1.0	8
31	FcγRI-Mediated Activation of Human Mast Cells Promotes Survival and Induction of the Pro-survival Gene Bfl-1. Journal of Clinical Immunology, 2008, 28, 250-255.	2.0	10
32	Is there a role for mast cells in psoriasis?. Archives of Dermatological Research, 2008, 300, 461-478.	1.1	108
33	NFAT but not NF-κB is critical for transcriptional induction of the prosurvival gene A1 after IgE receptor activation in mast cells. Blood, 2008, 111, 3081-3089.	0.6	31
34	FcεRI Aggregation Promotes Survival of Connective Tissue-Like Mast Cells but Not Mucosal-Like Mast Cells. Journal of Immunology, 2007, 178, 4177-4183.	0.4	32
35	The BH3-only protein Puma plays an essential role in cytokine deprivation–induced apoptosis of mast cells. Blood, 2007, 110, 3209-3217.	0.6	103
36	The Potential Role of Innate Immunity in the Pathogenesis of Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America, 2007, 21, 805-823.	0.9	27

GUNNAR NILSSON

#	Article	IF	CITATIONS
37	Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. British Journal of Haematology, 2007, 138, 68-71.	1.2	73
38	Expression of Mast Cell Tryptases in Hodgkin and Reed-Sternberg (HRS) Cells. Scandinavian Journal of Immunology, 2007, 67, 071117034935002-???.	1.3	0
39	Bcl-2 and Bcl-XL are indispensable for the late phase of mast cell development from mouse embryonic stem cells. Experimental Hematology, 2007, 35, 385-393.	0.2	17
40	Increase in CD30 ligand/CD153 and TNF-α expressing mast cells in basal cell carcinoma. Cancer Immunology, Immunotherapy, 2007, 56, 1407-1415.	2.0	21
41	Coaggregation of FcεRI with FcγRIIB Inhibits Degranulation but Not Induction of Bcl-2 Family Members A1 and Bim in Mast Cells. Allergy, Asthma and Clinical Immunology, 2006, 2, 87-97.	0.9	8
42	IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. European Journal of Haematology, 2006, 76, 278-283.	1.1	35
43	Readministration of IgE Is Required for Repeated Passive Cutaneous Anaphylaxis in Mice. International Archives of Allergy and Immunology, 2006, 141, 168-171.	0.9	6
44	Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. Journal of Clinical Investigation, 2006, 116, 2748-2756.	3.9	119
45	Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood, 2005, 106, 1330-1336.	0.6	109
46	Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. International Journal of Cancer, 2003, 107, 197-201.	2.3	111
47	Mast cell survival and apoptosis in organ-cultured human skin. Experimental Dermatology, 2003, 12, 53-60.	1.4	16
48	Selective CCL5/RANTES-induced mast cell migration through interactions with chemokine receptors CCR1 and CCR4. Biochemical and Biophysical Research Communications, 2002, 297, 480-485.	1.0	72
49	Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. British Journal of Haematology, 2002, 119, 122-124.	1.2	160
50	IgE-mediated mast cell degranulation and recovery monitored by time-lapse photographyâ~†. Journal of Allergy and Clinical Immunology, 2001, 108, 116-121.	1.5	61
51	Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. British Journal of Haematology, 2001, 114, 616-623.	1.2	116
52	Transforming growth factor-β-mediated mast cell migration depends on mitogen-activated protein kinase activity. Cellular Signalling, 2001, 13, 483-490.	1.7	53
53	Essential Role of the Prosurvival bcl-2 Homologue A1 in Mast Cell Survival After Allergic Activation. Journal of Experimental Medicine, 2001, 194, 1561-1570.	4.2	95
54	Human mast cell migration in response to members of the transforming growth factor-β family. Journal of Leukocyte Biology, 2000, 67, 350-356.	1.5	108

GUNNAR NILSSON

#	Article	IF	CITATIONS
55	The chemokine receptor CXCR4 is expressed within the mast cell lineage and its ligand stromal cell-derived factor-11± acts as a mast cell chemotaxin. European Journal of Immunology, 2000, 30, 3614-3622.	1.6	81
56	Mast Cell Migratory Response to Interleukin-8 Is Mediated Through Interaction With Chemokine Receptor CXCR2/Interleukin-8RB. Blood, 1999, 93, 2791-2797.	0.6	93
57	Serum Amyloid A Induces Chemotaxis of Human Mast Cells by Activating a Pertussis Toxin-Sensitive Signal Transduction Pathway. Biochemical and Biophysical Research Communications, 1999, 254, 143-146.	1.0	62
58	Human mast cells express functional TrkA and are a source of nerve growth factor. European Journal of Immunology, 1997, 27, 2295-2301.	1.6	209
59	Effects of interleukin (IL)-13 on immediate-early response gene expression, phenotype and differentiation of human mast cells. Comparison with IL-4. European Journal of Immunology, 1995, 25, 870-873.	1.6	67